Eris Lifesciences Ltd is the only publicly listed Indian pharmaceutical company with a pure-play domestic branded formulations business model. Established in 2007, Eris is by far the youngest company in the IPM Top-25. Our business ethos is based on two pillars – harnessing the power of cutting-edge science to bring evidence-based therapies to the market, and enabling our patients to take charge of their diagnoses and their lives through our patient care initiatives. Since inception, we have been focused on chronic and sub chronic lifestyle related therapies. We are a fully-integrated pan-India business with a strong focus on high-end super-specialist doctors and consulting physicians. Our revenues exceeded INR 1,200 crore for the year ended March 2021.
We continue to pioneer the generation of actionable medical evidence through initiatives such as the India Heart Study (IHS) and India Diabetes Study (IDS); these studies are helping create bodies of knowledge hitherto unknown and are paving the way for better management of health and treatment outcomes.